← Issue №11/
week of Sep 13, 2026/
the whole section, in full
Endoscopy, in full.
All 10 Endoscopy papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Endoscopyprospective cohort · n=109 · Sep 9, 2026 · GIE · IF 8.0
Clinical takeawayFor EUS patients undergoing the procedure and requiring cirrhosis assessment, perform right-lobe and splenic shear wave stiffness measurement using standard transducer pressure. Splenic measurement is highly accurate for cirrhosis detection (AUC 0.962), outperforming APRI and FIB4. Do not rely on EUS-SWM for intermediate fibrosis staging (F2-F3).
What it foundSplenic shear wave stiffness via EUS identified cirrhosis with AUC 0.962, outperforming APRI and FIB4; hepatic stiffness correlated strongly with histologic fibrosis (left lobe r=0.837-0.872, right lobe r=0.748-0.766).
ContextRefines non-invasive cirrhosis detection for the subset of patients already undergoing EUS, with superior accuracy compared to serology-based APRI and FIB4 scores. No head-to-head comparison with transient elastography, the current standard non-invasive test, so relative positioning unclear.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Kohli DR … Srikureja W · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopyguideline · Sep 9, 2026 · Clin Gastro Hep · IF 16.2
Clinical takeawayFor patients with suspected ampullary adenoma, use a side-viewing duodenoscope (not forward-viewing gastroscope) with careful biopsy technique-avoiding the pancreatic orifice to minimize pancreatitis risk-and obtain at least 6 biopsies, prioritizing ulcerated or indurated areas, to assess for occult malignancy. Perform EUS staging in adenomas considered for endoscopic resection, except lesions <1 cm with no worrisome features.
What it found20%-40% of ampullary adenomas harbor malignancy; AGA recommends side-viewing duodenoscope assessment with at least 6 biopsies from ulcerated or indurated areas, and EUS staging for adenomas amenable to endoscopic resection.
ContextAmpullary neoplasia is rare (0.6%-0.8% of GI cancers) with 5-year survival ranging 20%-75% by stage. This AGA expert review fills a documented gap in formalized guidance and standardizes assessment technique, particularly relevant given rising incidence in young adults.
Measured against the standard of care· AGA Clinical Practice Update (Expert Review) 2026 / ESGE 2021ShowHide
Decision at stakedetermine which ampullary adenomas are candidates for endoscopic versus surgical management
…SELECTION: AGA describes the lesion most amenable to papillectomy as having well-defined margins, size <4-5 cm, nonfriable tissue, softness to probing, and intraductal extension <=1 cm. AGA sets 3 absolute contraindications: metastatic spread; invasive cancer beyond the mucosa; and >1 cm intraductal extension in a surgically fit patient.…For >1 cm intraductal extension, AGA suggests surgical consultation; <1 cm may be treated endoscopically with close surveillance.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS, STAGING, TECHNIQUE and 5 more.
Our full summary of this standardShowHide
Two current documents govern ampullary adenoma: the AGA Clinical Practice Update expert review (Barakat, Maranki, Irani, Chahal; Clin Gastroenterol Hepatol, online 2026-09-09; ungraded Best Practice Advice from literature review plus expert opinion, no systematic review) and the ESGE 2021 graded guideline (Vanbiervliet et al., Endoscopy 2021;53:429-448), which it does not replace. DIAGNOSIS: both use a side-viewing duodenoscope. AGA adds that biopsies should avoid the pancreatic orifice to limit post-procedure pancreatitis. Because 20-40% of ampullary adenomas harbor malignancy, AGA advises AT LEAST 6 biopsies, targeting ulcerated or indurated areas. ESGE requires proven adenoma before papillectomy and recommends against diagnostic papillectomy. STAGING: AGA says to consider EUS for every adenoma potentially amenable to endoscopic resection, EXCEPT lesions <1 cm with no worrisome clinical or endoscopic features. ESGE recommends EUS plus MRCP (IDUS in selected patients) and advises against routine molecular testing of biopsies. SELECTION: AGA describes the lesion most amenable to papillectomy as having well-defined margins, size <4-5 cm, nonfriable tissue, softness to probing, and intraductal extension <=1 cm. AGA sets 3 absolute contraindications: metastatic spread; invasive cancer beyond the mucosa; and >1 cm intraductal extension in a surgically fit patient. Relative contraindications are size >5 cm, early-stage/T1 cancer, and likely poor follow-up adherence. For >1 cm intraductal extension, AGA suggests surgical consultation; <1 cm may be treated endoscopically with close surveillance. This is a stricter intraductal threshold than ESGE's, which suggests surgery only for intraductal involvement >20 mm and adjunct RFA or cystotome ablation with temporary biliary stenting for <=20 mm in expert centers. ESGE also gates en bloc resection at adenomas up to 20-30 mm and lists >4 cm or a periampullary diverticulum as technical reasons to consider surgery. TECHNIQUE: both say to avoid biliary or pancreatic sphincterotomy before papillectomy (AGA's reasons: cautery artifact and bleeding) and to use en bloc snare resection when feasible. Submucosal injection is generally not needed, except for a laterally spreading duodenal-wall component. ESGE also suggests endocut current. PANCREATITIS PROPHYLAXIS: AGA advises using ALL THREE together: prophylactic pancreatic duct stent, rectal NSAID, and high-volume lactated Ringer's. ESGE recommends the PD stent and rectal diclofenac or indomethacin 100 mg, with lactated Ringer's suggested mainly when stenting is not possible. BLEEDING: standard hemostasis methods (epinephrine, electrocoagulation, clips, APC, hemostatic sprays); ESGE says prophylactic hemostasis is individualized. BILIARY DRAINAGE when resection is not feasible: AGA allows drainage with or without sphincterotomy and SEMS for significant jaundice or cholangitis, at the surgeon's discretion. ESGE recommends against routine preoperative drainage, reserving it for cholangitis, severe jaundice, delayed surgery, or neoadjuvant therapy, with SEMS when drainage is needed. ADJUNCT/RESIDUAL: for adenomas >3 cm resected piecemeal or with positive margins, AGA advises considering adjunct thermal ablation plus ductography, repeated every 2-3 months until biopsy confirms eradication. ESGE allows APC and EMR for benign residual or recurrent lesions. SURVEILLANCE: both use the same schedule: side-viewing duodenoscopy with biopsy of the scar and any abnormal area at 3 months, then at 6 and 12 months, then yearly for at least 5 years. AGA says surveillance beyond 5 years should be individualized (recurrence risk, comorbidity, life expectancy) but is required if high-risk features are present. In FAP, AGA individualizes intervals by ampullary, gastric and duodenal disease burden. MALIGNANCY: AGA advises multidisciplinary discussion (GI, surgery, oncology) for high-grade dysplasia, incomplete resection, or suspected malignancy. ESGE recommends pancreaticoduodenectomy with lymphadenectomy for T1 or higher, and accepts local resection for Tis when final pathology shows no residual disease.
Barakat M … Chahal P · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Clinical takeawayApply topical 2% vitamin C solution or 10% N-acetylcysteine immediately after Lugol chromoendoscopy to reduce post-procedure discomfort. At 15 minutes, symptom rates drop from 44% (saline) to 8-9%; at 30 minutes from 32% to 4%. This simple intervention requires no special equipment beyond standard endoscopy supplies.
What it foundTopical 2% vitamin C solution and 10% N-acetylcysteine each reduced post-Lugol symptoms to 8.8% and 9.4% incidence at 15 minutes, versus 44.3% with saline (relative risks 0.198 and 0.213), and to 4.2% and 4.1% at 30 minutes (relative risks 0.132 and 0.129).
ContextLugol chromoendoscopy detects esophageal squamous neoplasia effectively but has been limited by short-term pharyngeal and retrosternal discomfort. This is the first randomized evidence that immediate topical application of vitamin C or NAC substantially reduces symptoms, offering a practical in-procedure tool to improve screening tolerance.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Fu X … Tian S · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
Clinical takeawayFor intermediate-likelihood CBD stones, EUS and MRCP remain diagnostically equivalent per guidelines. On carbon-intensive grids, EUS reduces per-procedure emissions 4.2-fold compared to MRCP (4.53 vs 18.90 kg CO2e), adding environmental impact to the accuracy, safety, and cost decision. On low-carbon grids, this advantage narrows and may not apply. Where available and suitable, consider EUS accounting for local grid carbon intensity, patient preference, and local expertise.
What it foundEUS generated 4.53 kg CO2e per procedure versus MRCP 18.90 kg CO2e (4.2-fold difference); MRCP's continuous cryocooler standby was the largest single contributor to emissions (23.4%).
ContextConfirms diagnostic equivalence of EUS and MRCP per guidelines. Introduces environmental footprint as a new decision discriminator; this is the first direct carbon comparison of these two biliary imaging modalities. Environmental advantage is greatest on carbon-intensive grids.
Refinessuggested applicable standard· American Society for Gastrointestinal Endoscopy (ASGE), "ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis" (Buxbaum JL et al., Gastrointest Endosc 2019;89(6):1075-1105), 2019ShowHide
Decision at stakeWhich confirmatory imaging modality to use for intermediate-likelihood choledocholithiasis
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Risk-stratify suspected choledocholithiasis (high >50%, intermediate 10-50%, low <10% probability). HIGH-risk criteria, any of which should directly prompt ERCP: (1) CBD stone on ultrasound or cross-sectional imaging; (2) ascending cholangitis; (3) total bilirubin >4 mg/dL AND dilated CBD (>6 mm in adults with gallbladder in situ, >8 mm after cholecystectomy). Gallstone pancreatitis was deliberately REMOVED as a high-risk criterion in the 2019 revision. INTERMEDIATE risk (abnormal liver biochemical tests, age >55 y, or bile-duct dilation on imaging): the panel suggests confirmation with either EUS or MRCP (conditional recommendation, low-quality evidence; choice by patient preference, local expertise, availability), laparoscopic intraoperative cholangiography (IOC) or intraoperative US are equally sanctioned alternatives. LOW risk: cholecystectomy with or without IOC/intraoperative US if indicated for symptomatic cholelithiasis; no ERCP and no mandatory advanced biliary imaging. In gallstone pancreatitis WITHOUT cholangitis or biliary obstruction/choledocholithiasis, the panel recommends AGAINST urgent (<48 h) ERCP (strong recommendation, low-quality evidence). Same-admission cholecystectomy is recommended for patients with MILD gallstone pancreatitis (consensus, PONCHO-based); ERCP with prophylactic sphincterotomy should not be used as an alternative to cholecystectomy unless surgery is absolutely contraindicated (e.g., recurrent pancreatitis in end-stage liver disease). For large bile-duct stones, the panel suggests endoscopic sphincterotomy followed by large-balloon dilation (ES-LBD) rather than sphincterotomy alone (conditional, moderate); for large AND difficult stones, it suggests intraductal therapy (cholangioscopy-guided EHL or laser lithotripsy) or conventional therapy with papillary dilation, chosen by local expertise, cost, and patient/physician preference (conditional, very low). Timing versus cholecystectomy: pre- or postoperative ERCP or laparoscopic bile-duct clearance for patients at high risk or with positive IOC, depending on local surgical and endoscopic expertise (consensus).
New evidencefamilial adenomatous polyposispolypectomy
Clinical takeawayFor FAP patients with duodenal lesions, endoscopic surveillance with cold snare polypectomy is safe and effective; for ampullary lesions, selective papillectomy carries low morbidity and low progression risk (selection criteria detailed in the source). This tertiary-center experience supports systematic endoscopic management as feasible in referral practice.
What it foundEndoscopic surveillance and treatment at a tertiary FAP center (233 patients, 862 EGDs, 10 years) treated 208 duodenal lesions with low-grade dysplasia in 72.4%, high-grade dysplasia in 25.9%, adenocarcinoma in 1.7%; cold snare polypectomy was most common (41.9%). Among 47 ampullary lesions, 78.7% managed with surveillance, 21.3% with papillectomy.
ContextThis observational series from a single tertiary center demonstrates safety and feasibility of endoscopic surveillance and treatment for FAP duodenal and ampullary lesions; provides supportive evidence for current surveillance strategies but does not establish comparative benefit against alternative surveillance structures.
Measured against the standard of care· ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.)ShowHide
Decision at stakeWhether to actively treat duodenal lesions detected during EGD surveillance in FAP versus observation only
…For FAP, AFAP and MAP, upper endoscopic surveillance that includes viewing the duodenal papilla is suggested over no surveillance (Recommendation 8, conditional).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Polyposis syndromes are now governed by ACG 2026 (Mankaney G, Idos GE, Stoffel EM, Weiss JM, Shah S, Qayed E, Harnegie MP, Burke CA; Am J Gastroenterol 2026;121(9):2086-2120, GRADE). For polyposis, it replaces the 2015 ACG hereditary GI cancer guideline (Syngal et al.), Recommendations 10-11. Germline multigene panel testing is recommended for anyone with 20 or more cumulative lifetime colorectal adenomas (strong recommendation) and suggested for 10-19 adenomas (conditional, because the yield is lower). The 2015 polyposis testing trigger was more than 10 adenomas. Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. Colonoscopy then repeats every 1-3 years depending on the histology, size and number of polyps. It moves to every 3-6 months when there are many or large polyps, or high-grade dysplasia. This replaces the 2015 schedules of annual sigmoidoscopy/colonoscopy from puberty for classic FAP, colonoscopy every 1-2 years from the late teens for AFAP, and from age 25-30 for MAP. Whether at-risk children in classic-FAP families still start younger is not stated in the excerpt available at review; confirm against the full text. For FAP, AFAP and MAP, upper endoscopic surveillance that includes viewing the duodenal papilla is suggested over no surveillance (Recommendation 8, conditional). Duodenal management is still staged by Spigelman, which has acknowledged limits in sensitivity for duodenal and papillary cancer. The 2026 starting age and intervals for upper endoscopy are not stated in the excerpt available at review. The choice of operation (total colectomy with IRA, IPAA, or end ileostomy) is individualized by genotype, polyp distribution, cancer status, comorbidity and preference, with early referral to an experienced colorectal surgeon. IRA is generally favored with up to about 20 rectal adenomas and IPAA above that, though this is not a fixed cutoff. The rectum or pouch should be checked endoscopically every year after IRA or IPAA. Chemoprevention is recommended against as a substitute for colectomy when surgery is indicated. Whether 2026 keeps annual thyroid ultrasound is not stated in the excerpt available at review. Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.
Scardino A … Rausa E · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Clinical takeawayAdopt PREFERENDO's 27 consensus reporting standards for pediatric colonoscopy. Standardize your colonoscopy reports to include: defined report structure, physiological and pathological descriptors using endorsed terminology, bowel preparation quality assessment, terminal ileum intubation documentation, endorsed endoscopic scoring systems, and standardized lesion and polypectomy characterization. Specific criteria for each element are detailed in the source paper.
What it found27 of 31 Delphi consensus statements were approved; the manuscript specifically presents results for pediatric colonoscopy reporting standards, covering report structure, physiological and pathological descriptors, bowel preparation, terminal ileum intubation, endoscopic scoring systems, and polypectomy characterization.
ContextPrior pediatric endoscopy documentation was heterogeneous with no agreed international standard. PREFERENDO provides the first major consensus framework for standardized pediatric GI endoscopy reporting, enabling consistent documentation across centers and supporting quality harmonization.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Chiaro A … SIGENP Endoscopy Working Group · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Clinical takeawayIn selected patients where clinical and imaging features suggest pancreatic cancer, PD brushing with combined BC and FISH can assist diagnosis, but 54.3% sensitivity cannot exclude malignancy if negative (confirmatory EUS-guided biopsy or surgery remains necessary). The 7.8% post-ERCP pancreatitis rate, notably higher than baseline diagnostic ERCP, warrants careful patient selection and informed consent.
What it foundCombined pancreatic duct brushing and FISH achieved 54.3% sensitivity and 87.7% specificity for detecting pancreatic cancer (AUC 0.71); post-ERCP pancreatitis occurred in 7.8% of 205 subjects.
ContextPD brushing with FISH is an existing technique that has been underutilized due to sparse systematic data on diagnostic accuracy. This retrospective analysis provides the first formal evaluation showing that combined brush cytology plus FISH yields modest diagnostic performance, insufficient as a standalone diagnostic modality but useful as an adjunctive tool.
Reinforcessuggested applicable standard· American Society for Gastrointestinal Endoscopy (ASGE), 'American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations' (Buxbaum JL et al., Gastrointest Endosc 2023;97(2):153-162). DOI 10.1016/j.gie.2022.10.005, PMID 36517310.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
For ALL patients undergoing ERCP (average-risk and high-risk alike), give periprocedural rectal NSAID prophylaxis (100 mg indomethacin or diclofenac) unless contraindicated (e.g., recent PUD, renal insufficiency), this is now a strong recommendation for unselected patients, not just high-risk ones. For high-risk patients undergoing repeated or deep pancreatic-duct access or ampullectomy, add a prophylactic small-caliber pancreatic duct stent (3-5Fr, preferably 5Fr, 3-7cm, removed within 5-10 days), strong recommendation; for other high-risk scenarios (difficult cannulation, prior PEP, precut sphincterotomy without fistulotomy), PD stenting is a conditional recommendation when PD access is easily achieved. Aggressive periprocedural/postprocedural IV hydration with lactated Ringer's (20 mL/kg bolus, then 3 mL/kg/h for 8h) is a conditional suggestion for unselected patients (most practical for inpatients), and wire-guided cannulation is conditionally favored over contrast-guided to reduce PEP risk. The SVI trial (Elmunzer, Lancet 2024) found rectal indomethacin alone did NOT meet non-inferiority versus indomethacin+stent in high-risk patients (PEP 14.9% vs 11.3%), supporting continued use of the combination bundle in high-risk cases rather than dropping the stent. Post-procedure, monitor for the major complications (pancreatitis, sphincterotomy bleeding, perforation, cholangitis) and manage by type, PEP by Cotton criteria with fluids/analgesia, bleeding with repeat endoscopic hemostasis, perforation by Stapfer classification with surgical consult for Type I, and cholangitis with empiric antibiotics (Tokyo Guidelines TG18) plus biliary drainage; these complication-management elements are unchanged from ESGE 2020.
Clinical takeawayNo established clinical advantage demonstrated. MANTIS Clip achieves high initial closure (95.2%), but efficacy is size-dependent: 100% successful closure for specimens ≤59 mm but only 75% for specimens ≥60 mm. Study protocol targeted 30-50 mm lesions but included larger specimens with lower success. Sustained closure was only 76.2% at 3-5 days with 95.2% clip dislodgement by 2 weeks. Low adverse-event rates (0% delayed bleeding/perforation) are encouraging in this small series but lack a control group. Cannot determine whether clip placement prevents complications compared to standard practice or defects left open. Adoption should await comparative trial data stratified by defect size.
What it foundComplete closure achieved in 95.2% (20/21) of defects with MANTIS Clip, but sustained closure in only 76.2% (16/21) at 3-5 days with 95.2% clip dislodgement by ≥2 weeks; delayed bleeding and perforation rates were 0%, post-ESD coagulation syndrome occurred in 14.3%.
ContextRecent Tier 2 literature reports a prospective single-center evaluation of an anchor-pronged clip device (MANTIS Clip) for complete closure of large colorectal post-ESD defects, demonstrating feasibility and potential to address delayed adverse events from inadequate defect healing.
Emergingsuggested applicable standard· Society of Critical Care Medicine / European Society of Intensive Care Medicine, "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026", 2026ShowHide
Decision at stakeHow to achieve durable closure of large mucosal defects after colorectal ESD to prevent delayed complications
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Triage suspected perforation with immediate IV access (2 large-bore IVs) and assessment of perfusion in parallel with diagnostics; obtain upright CXR and CT abdomen/pelvis (most sensitive/specific) plus labs and lactate, and start empiric broad-spectrum antibiotics. Fluid therapy is stratified by perfusion status, not given as a fixed protocol for all comers: in adults with sepsis-induced hypoperfusion or septic shock, give at least 30 mL/kg IV crystalloid within the first 3 hours (Surviving Sepsis Campaign 2026; conditional recommendation, low-certainty evidence), selecting the initial volume by individual patient characteristics and context (use adjusted or ideal body weight if BMI >30 kg/m²) with frequent, ongoing reassessment to avoid under- or over-resuscitation, alongside sepsis care: blood cultures as soon as possible and ideally before antimicrobials, lactate with serial measurement to guide resuscitation, and vasopressors if hypotension persists despite fluids. In patients without sepsis-induced hypoperfusion or shock, do not give protocolized volume resuscitation; use maintenance fluids or small individualized boluses guided by hemodynamic reassessment, and in fluid-sensitive patients (e.g., heart failure, end-stage renal disease) use smaller individualized boluses with close reassessment rather than a fixed weight-based volume. Obtain mandatory emergency surgical consultation for any confirmed perforation, hard peritoneal signs, free air, or hemodynamic instability, proceeding to exploratory laparotomy/laparoscopy or cause-specific surgery (Graham patch, Hartmann, colectomy). Selected contained post-procedural perforations that are small, clip-amenable, and hemodynamically stable may be managed conservatively with ICU monitoring, NPO, antibiotics, and serial imaging.
Clinical takeawayIn patients with borderline acid exposure (AET 4-6%), lower MNBI (< 1618 Ω) supports diagnosis of pathological GERD and consideration of treatment; this threshold may help navigate the diagnostic gap between Lyon Consensus 2.0 (AET ≥ 6%) and East Asian standards (AET ≥ 4%). However, these cutoffs are internally derived and require external validation before routine adoption in other populations.
What it foundLower mean nocturnal baseline impedance independently predicted pathological AET ≥ 6% (OR 0.84 per 100-unit increase, p < 0.001), with an exploratory cutoff of 1618 Ω achieving AUC 0.883.
ContextMNBI is already used to characterize reflux burden, but the diagnostic gray zone between international and regional AET thresholds has created clinical uncertainty in borderline cases. This study provides a physiological marker to resolve that ambiguity in a Korean cohort, though the cutoff remains unvalidated externally.
Refinessuggested applicable standard· American College of Gastroenterology (ACG), ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ), Am J Gastroenterol 2022;117(1):27-56ShowHide
Decision at stakehow to characterize GERD in patients with borderline acid exposure time in the 4-6% AET gray zone
…Where GERD is suspected but unclear and endoscopy shows no objective evidence, perform reflux monitoring OFF therapy to establish the diagnosis (strong, low); conversely, do NOT perform off-therapy reflux monitoring solely as a diagnostic test in patients already known to have LA grade C or D esophagitis or long-segment Barrett's, because the diagnosis is already established (strong, low).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
In patients with classic GERD symptoms (heartburn, regurgitation) and no alarm symptoms, give an 8-week trial of empiric PPI ONCE DAILY before a meal (strong, moderate evidence); administer PPI 30-60 minutes before a meal rather than at bedtime (strong, moderate). Endoscopy is the FIRST test in patients presenting with dysphagia or other alarm symptoms, the guideline names weight loss and GI bleeding, and also in patients with multiple risk factors for Barrett's esophagus (strong, low). If classic symptoms respond to the 8-week trial, attempt to discontinue the PPI (conditional, low); for patients without erosive esophagitis or Barrett's whose symptoms resolved, an attempt at discontinuation should be made; patients requiring maintenance should take the lowest effective dose. If symptoms do not respond adequately to the 8-week trial, or return on discontinuation, perform diagnostic endoscopy, ideally after PPIs are stopped for 2-4 weeks (strong, low). Where GERD is suspected but unclear and endoscopy shows no objective evidence, perform reflux monitoring OFF therapy to establish the diagnosis (strong, low); conversely, do NOT perform off-therapy reflux monitoring solely as a diagnostic test in patients already known to have LA grade C or D esophagitis or long-segment Barrett's, because the diagnosis is already established (strong, low). In refractory GERD, optimize PPI therapy first (strong, moderate); then pH monitoring OFF PPIs if GERD was not previously established by pH study, long-segment Barrett's, or LA grade C/D esophagitis, versus impedance-pH ON PPIs where GERD is already established but symptoms persist on twice-daily PPI (both conditional, low). Before antireflux surgery or endoscopic therapy, HRM is recommended to rule out achalasia and absent contractility, with provocative testing (e.g., multiple rapid swallows) to identify contractile reserve in ineffective esophageal motility; on-therapy reflux monitoring is suggested before intervention in patients with prior objective GERD findings who remain symptomatic. Antireflux surgery by an experienced surgeon is an option for patients with OBJECTIVE evidence of GERD, with severe esophagitis (LA C/D), large hiatal hernia, or persistent troublesome symptoms benefiting most; TIF is suggested only for troublesome regurgitation or heartburn in patients who do not wish to undergo antireflux surgery and who are WITHOUT severe esophagitis (LA C/D) or hiatal hernia >2 cm. For extraesophageal symptoms WITHOUT typical GERD symptoms, perform reflux testing BEFORE starting PPI therapy (strong, moderate); with concomitant typical symptoms, consider twice-daily PPI for 8-12 weeks before further testing (conditional, low). Lifestyle: weight loss in overweight/obese patients (strong, moderate); avoid meals within 2-3 hours of bedtime, avoid tobacco, avoid trigger foods, and elevate the head of the bed for nighttime symptoms (all conditional, low).
Clinical takeawayEpidemiological surveillance data; no new treatment recommendations. Clinical relevance: alcohol-related CP accounts for 39.5% of female cases in Japan, a substantial proportion warranting attention to alcohol history when women present with CP. Maintain standard management: monitor for diabetes (45.8%), pancreatic exocrine insufficiency (36.6%), and malignancy (18%) per established guidelines.
What it foundCP prevalence in Japan increased 30% to 58.6 per 100,000 population (2016-2021), with 17,490 new cases annually (incidence 13.9 per 100,000). Alcohol was the etiology in 69.6% of cases overall and 39.5% of female cases.
ContextJapan-specific epidemiological survey updating 2016 nationwide data. The 30% prevalence increase and the substantial proportion of alcohol-related CP among women (39.5%) reflect the current disease burden in Japan. Reinforces need for comprehensive long-term management of CP complications and attention to alcohol-related cases in both sexes.
Reinforcessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.ShowHide
Decision at stakescreen for and manage diabetes, exocrine insufficiency, and malignancy in chronic pancreatitis
…Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.